Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer

Part of differentiated thyroid cancer will relapse or develop into dedifferentiated thyroid cancer after standard therapy, such as surgery or radionuclide therapy. Sorafenib (SOR) is recommended for the treatment of advanced or radioiodine-refractory thyroid cancer. The monotherapy using SOR is ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shijie, Dong, Shujun, Xu, Weiguo, Jiang, Yang, Li, Zhongmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008594/
https://www.ncbi.nlm.nih.gov/pubmed/32116677
http://dx.doi.org/10.3389/fphar.2019.01676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008594/
https://www.ncbi.nlm.nih.gov/pubmed/32116677
http://dx.doi.org/10.3389/fphar.2019.01676

Ejemplares similares